AAPL343.46+1.46 (+0.43%) ▲|ABBV285.42+2.02 (+0.71%) ▲|ABT104.89+0.21 (+0.20%) ▲|ACN229.68+4.76 (+2.12%) ▲|ADBE245.20-6.47 (-2.57%) ▼|AMAT409.29-20.72 (-4.82%) ▼|AMD528.75-33.48 (-5.95%) ▼|AMGN432.49-1.54 (-0.35%) ▼|AMT185.27+3.91 (+2.16%) ▲|AMZN250.00-4.76 (-1.87%) ▼|AVGO328.75-15.58 (-4.52%) ▼|AXP313.59-0.28 (-0.09%) ▼|BA190.21+1.48 (+0.78%) ▲|BAC51.23-0.47 (-0.91%) ▼|BKNG163.45-2.35 (-1.42%) ▼|BLK1,134.38+13.60 (+1.21%) ▲|BMY59.75-0.82 (-1.35%) ▼|BNY143.30+1.21 (+0.85%) ▲|BRK-B532.02+6.34 (+1.21%) ▲|C124.26+1.05 (+0.85%) ▲|CAT730.76-4.88 (-0.66%) ▼|CL94.11+1.44 (+1.55%) ▲|CMCSA21.90+0.13 (+0.60%) ▲|COF201.74+2.88 (+1.45%) ▲|COP146.51+4.78 (+3.37%) ▲|COST989.11+11.10 (+1.14%) ▲|CRM240.70-6.04 (-2.45%) ▼|CSCO107.39-2.46 (-2.24%) ▼|CVS92.36-0.22 (-0.24%) ▼|CVX224.99+5.67 (+2.59%) ▲|DE641.86-8.81 (-1.35%) ▼|DHR229.04-2.46 (-1.06%) ▼|DIS110.59-0.09 (-0.08%) ▼|DUK121.47+2.59 (+2.18%) ▲|EMR161.47-0.68 (-0.42%) ▼|FDX293.55-1.99 (-0.67%) ▼|GD344.23+7.20 (+2.14%) ▲|GE313.83+1.83 (+0.59%) ▲|GEV921.20-5.24 (-0.57%) ▼|GILD156.19-1.18 (-0.75%) ▼|GM83.96+0.30 (+0.36%) ▲|GOOG336.91-8.00 (-2.32%) ▼|GOOGL340.59-8.63 (-2.47%) ▼|GS881.26-10.02 (-1.12%) ▼|HD309.63+1.39 (+0.45%) ▲|HON211.41+0.91 (+0.43%) ▲|IBM232.14-1.98 (-0.85%) ▼|INTC89.85-5.52 (-5.79%) ▼|INTU325.15-5.02 (-1.52%) ▼|ISRG426.70-1.16 (-0.27%) ▼|JNJ255.56+2.28 (+0.90%) ▲|JPM339.72+4.19 (+1.25%) ▲|KO93.90+1.90 (+2.07%) ▲|LIN498.43+5.21 (+1.06%) ▲|LLY1,257.03+5.42 (+0.43%) ▲|LMT552.09+19.45 (+3.65%) ▲|LOW197.38+1.66 (+0.85%) ▲|LRCX263.94-13.52 (-4.87%) ▼|MA617.42+1.10 (+0.18%) ▲|MCD242.97+0.47 (+0.19%) ▲|MDLZ63.91+0.88 (+1.40%) ▲|MDT94.75-0.70 (-0.73%) ▼|META709.33-27.40 (-3.72%) ▼|MMM164.75-0.58 (-0.35%) ▼|MO75.11+1.27 (+1.72%) ▲|MRK145.95+0.76 (+0.52%) ▲|MS180.57-1.53 (-0.84%) ▼|MSFT529.05-10.39 (-1.93%) ▼|MU878.84-52.40 (-5.63%) ▼|NEE79.80+0.84 (+1.06%) ▲|NFLX70.53-2.08 (-2.86%) ▼|NKE37.13-0.01 (-0.03%) ▼|NOW141.97-6.60 (-4.44%) ▼|NVDA214.13-3.10 (-1.43%) ▼|ORCL128.23-6.24 (-4.64%) ▼|PEP131.49+3.11 (+2.42%) ▲|PFE29.58+0.14 (+0.48%) ▲|PG159.35+2.27 (+1.45%) ▲|PLTR186.03-14.47 (-7.22%) ▼|PM205.20+5.30 (+2.65%) ▲|QCOM172.11-6.29 (-3.53%) ▼|RTX193.92+6.97 (+3.73%) ▲|SBUX97.52+0.64 (+0.66%) ▲|SCHW91.96-2.20 (-2.34%) ▼|SO91.18+2.00 (+2.24%) ▲|SPG205.44+2.05 (+1.01%) ▲|T23.44-0.06 (-0.26%) ▼|TMO690.00-6.49 (-0.93%) ▼|TMUS159.10+2.07 (+1.32%) ▲|TSLA354.72-7.72 (-2.13%) ▼|TXN276.48-2.64 (-0.95%) ▼|UBER70.35-0.92 (-1.29%) ▼|UNH401.43-5.24 (-1.29%) ▼|UNP289.04+0.33 (+0.11%) ▲|UPS97.48-0.35 (-0.36%) ▼|USB58.73+1.34 (+2.33%) ▲|V402.61+2.86 (+0.72%) ▲|VZ44.79+0.39 (+0.88%) ▲|WFC83.87+1.12 (+1.35%) ▲|WMT118.81+0.94 (+0.80%) ▲|XOM178.98+4.30 (+2.46%) ▲|AAPL343.46+1.46 (+0.43%) ▲|ABBV285.42+2.02 (+0.71%) ▲|ABT104.89+0.21 (+0.20%) ▲|ACN229.68+4.76 (+2.12%) ▲|ADBE245.20-6.47 (-2.57%) ▼|AMAT409.29-20.72 (-4.82%) ▼|AMD528.75-33.48 (-5.95%) ▼|AMGN432.49-1.54 (-0.35%) ▼|AMT185.27+3.91 (+2.16%) ▲|AMZN250.00-4.76 (-1.87%) ▼|AVGO328.75-15.58 (-4.52%) ▼|AXP313.59-0.28 (-0.09%) ▼|BA190.21+1.48 (+0.78%) ▲|BAC51.23-0.47 (-0.91%) ▼|BKNG163.45-2.35 (-1.42%) ▼|BLK1,134.38+13.60 (+1.21%) ▲|BMY59.75-0.82 (-1.35%) ▼|BNY143.30+1.21 (+0.85%) ▲|BRK-B532.02+6.34 (+1.21%) ▲|C124.26+1.05 (+0.85%) ▲|CAT730.76-4.88 (-0.66%) ▼|CL94.11+1.44 (+1.55%) ▲|CMCSA21.90+0.13 (+0.60%) ▲|COF201.74+2.88 (+1.45%) ▲|COP146.51+4.78 (+3.37%) ▲|COST989.11+11.10 (+1.14%) ▲|CRM240.70-6.04 (-2.45%) ▼|CSCO107.39-2.46 (-2.24%) ▼|CVS92.36-0.22 (-0.24%) ▼|CVX224.99+5.67 (+2.59%) ▲|DE641.86-8.81 (-1.35%) ▼|DHR229.04-2.46 (-1.06%) ▼|DIS110.59-0.09 (-0.08%) ▼|DUK121.47+2.59 (+2.18%) ▲|EMR161.47-0.68 (-0.42%) ▼|FDX293.55-1.99 (-0.67%) ▼|GD344.23+7.20 (+2.14%) ▲|GE313.83+1.83 (+0.59%) ▲|GEV921.20-5.24 (-0.57%) ▼|GILD156.19-1.18 (-0.75%) ▼|GM83.96+0.30 (+0.36%) ▲|GOOG336.91-8.00 (-2.32%) ▼|GOOGL340.59-8.63 (-2.47%) ▼|GS881.26-10.02 (-1.12%) ▼|HD309.63+1.39 (+0.45%) ▲|HON211.41+0.91 (+0.43%) ▲|IBM232.14-1.98 (-0.85%) ▼|INTC89.85-5.52 (-5.79%) ▼|INTU325.15-5.02 (-1.52%) ▼|ISRG426.70-1.16 (-0.27%) ▼|JNJ255.56+2.28 (+0.90%) ▲|JPM339.72+4.19 (+1.25%) ▲|KO93.90+1.90 (+2.07%) ▲|LIN498.43+5.21 (+1.06%) ▲|LLY1,257.03+5.42 (+0.43%) ▲|LMT552.09+19.45 (+3.65%) ▲|LOW197.38+1.66 (+0.85%) ▲|LRCX263.94-13.52 (-4.87%) ▼|MA617.42+1.10 (+0.18%) ▲|MCD242.97+0.47 (+0.19%) ▲|MDLZ63.91+0.88 (+1.40%) ▲|MDT94.75-0.70 (-0.73%) ▼|META709.33-27.40 (-3.72%) ▼|MMM164.75-0.58 (-0.35%) ▼|MO75.11+1.27 (+1.72%) ▲|MRK145.95+0.76 (+0.52%) ▲|MS180.57-1.53 (-0.84%) ▼|MSFT529.05-10.39 (-1.93%) ▼|MU878.84-52.40 (-5.63%) ▼|NEE79.80+0.84 (+1.06%) ▲|NFLX70.53-2.08 (-2.86%) ▼|NKE37.13-0.01 (-0.03%) ▼|NOW141.97-6.60 (-4.44%) ▼|NVDA214.13-3.10 (-1.43%) ▼|ORCL128.23-6.24 (-4.64%) ▼|PEP131.49+3.11 (+2.42%) ▲|PFE29.58+0.14 (+0.48%) ▲|PG159.35+2.27 (+1.45%) ▲|PLTR186.03-14.47 (-7.22%) ▼|PM205.20+5.30 (+2.65%) ▲|QCOM172.11-6.29 (-3.53%) ▼|RTX193.92+6.97 (+3.73%) ▲|SBUX97.52+0.64 (+0.66%) ▲|SCHW91.96-2.20 (-2.34%) ▼|SO91.18+2.00 (+2.24%) ▲|SPG205.44+2.05 (+1.01%) ▲|T23.44-0.06 (-0.26%) ▼|TMO690.00-6.49 (-0.93%) ▼|TMUS159.10+2.07 (+1.32%) ▲|TSLA354.72-7.72 (-2.13%) ▼|TXN276.48-2.64 (-0.95%) ▼|UBER70.35-0.92 (-1.29%) ▼|UNH401.43-5.24 (-1.29%) ▼|UNP289.04+0.33 (+0.11%) ▲|UPS97.48-0.35 (-0.36%) ▼|USB58.73+1.34 (+2.33%) ▲|V402.61+2.86 (+0.72%) ▲|VZ44.79+0.39 (+0.88%) ▲|WFC83.87+1.12 (+1.35%) ▲|WMT118.81+0.94 (+0.80%) ▲|XOM178.98+4.30 (+2.46%) ▲|
14.6 C
New York
Sunday, October 18, 2026

Tag: animal

newssourceFORcompanycontentinformation1releasesmarket

The American Kennel Club/AKC Canine Health Foundation Announce First Cornell Sports Medicine & Rehabilitation Resident

RALEIGH, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- The AKC Canine Health Foundation (CHF), in collaboration with the American Kennel Club (AKC®), is pleased to announce that the Cornell University College of Veterinary Medicine has matched its first resident funded through the second annual AKC/AKC CHF Canine Sports Medicine & Rehabilitation Residency Program award. Dr. Gabriela Medrano will begin her training with the program this fall.

HkeyBio Launches “NHP Fast-PoC” Program to Deliver Low-Cost Cyno PK/PD and Developability Data Amid Rising NHP Prices

The cost-effective platform delivers rapid pharmacological validation data in cynomolgus monkeys, helping biotech firms make confident R&D decisions before committing to full-scale IND studies.BOSTON...

Harbour BioMed Announces NMPA Acceptance of IND Application for HBM7004 for the Treatment of Advanced Solid Tumors

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 10, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the...

/C O R R E C T I O N — Lillie&Lee/

In the news release, America's Most-Followed Pet Wellness Brand Commits to Third-Party Testing Its Whole Line, issued 09-Jun-2026 by Lillie&Lee over PR Newswire, we...

Albert Einstein College of Medicine Launches BIO-VITAL to Accelerate Gerotherapeutics

New Program Connects Biotech and Pharmaceutical Partners with Einstein's Aging Research Expertise and Scientific Infrastructure BRONX, N.Y., June 9, 2026 /PRNewswire/ -- Albert Einstein...

Saputo Issues its 2026 Promise Report

MONTRÉAL, June 08, 2026 (GLOBE NEWSWIRE) -- On June 4, 2026, Saputo Inc. (TSX: SAP) (we, Saputo or the Company) issued its 2026 Saputo Promise Report, which highlights progress in key Environmental, Social, and Governance (ESG) priorities that support operational resilience, disciplined long-term growth, and sustainable value creation.

Godrej Industries Group Celebrates Pride@Godrej 2026

~ Godrej DEI Lab Launches Queer India Now!, a new anthology Under Queer Directions ~~ Introduces 'Queer India Fellowship' to Nurture Emerging Queer Leaders...

Virbac: modalités de mise à disposition ou de consultation des documents préparatoires à l’assemblée générale mixte du 29 juin 2026

Les actionnaires de la société VIRBAC sont invités à participer à l’assemblée générale mixte qui se tiendra le lundi 29 juin 2026 à 14 heures, dans les bâtiments de VIRBAC direction, 13ème rue LID 06517 Carros. 

Dong Bang Co Ltd Strengthens Global Competitiveness with Advanced Veterinary Pharmaceuticals

SEOUL, South Korea, June 8, 2026 /PRNewswire/ -- Dong Bang Co Ltd is strengthening its position in the global veterinary pharmaceutical market with high-value...

Expanding its partnership with non-profits, EZVIZ upgrades its Green Initiative to make a true impact on harmony between humans and nature with a week-long...

HOOFDDORP, Netherlands, June 8, 2026 /PRNewswire/ -- EZVIZ, a world-leading smart home brand, announced to enter a new chapter of its EZVIZ Green Initiative by expanding...

AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS

VESALIUS-CV Subgroup Results Show Repatha® Reduces Risk of First Major Cardiovascular Events by 29% in People Living with High-Risk DiabetesNew Real-World Data Highlight Treatment...

Zealand Pharma announces Boehringer Ingelheim’s survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while...

Company announcement No. 21 / 2026

Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting...

Ingelheim, Germany - Boehringer Ingelheim today announced positive results from two global Phase III trials of its glucagon/GLP-1 dual agonist survodutide (BI 456906), SYNCHRONIZE-1 and SYNCHRONIZE-MASLD.2,4 The results demonstrate survodutide’s potential to reduce weight and therefore improve metabolic health in two distinct populations: adults living with obesity or overweight, without type 2 diabetes (SYNCHRONIZE-1),2 and adults with overweight or obesity with metabolic dysfunction-associated steatotic liver disease (MASLD) with evidence of inflammation and or fibrosis (SYNCHRONIZE-MASLD).4 Full results from SYNCHRONIZE-1 and SYNCHRONIZE-MASLD were presented today at the American Diabetes Association’s (ADA) 2026 Scientific Sessions and published simultaneously in The New England Journal of Medicine and Nature Medicine respectively.5,6

Her Bodhi Claims Evaluated: What Research Reveals About This Primal Queen Alternative, Weight Loss Support and Consumer Reviews

An independent, research-informed evaluation of the Her Bodhi botanical formula — examining its ingredient benefits, weight loss positioning, menopause wellness support, disclosed side effects, and publicly available consumer feedback. 
An independent, research-informed evaluation of the Her Bodhi botanical formula — examining its ingredient benefits, weight loss positioning, menopause wellness support, disclosed side effects, and publicly available consumer feedback.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsAnimal

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers